Sign in

    Transcode Therapeutics (RNAZ)

    Q1 2025 Earnings Summary

    Reported on Jan 1, 1970
    Pre-Earnings PriceN/ADate unavailable
    Post-Earnings PriceN/ADate unavailable
    Price ChangeN/A
    MetricYoY ChangeReason

    Total Revenue

    Remained at $0

    Revenue remains unchanged at $0 in Q1 2025 as the company is still in its pre-revenue phase, consistent with prior periods.

    Operating Loss

    Improved by approximately 3.5% (from a loss of $3.29 million to $3.17 million)

    The modest improvement in operating loss reflects slight operational efficiencies and cost management improvements relative to Q1 2024, despite ongoing high operating expenses.

    Research and Development (R&D)

    Increased by 26% YoY to about $2.22 million

    R&D spending rose significantly as increased clinical trial start-up costs and related activities boosted expenditures, following a lower baseline in Q1 2024.

    General & Administrative (G&A)

    Decreased by 38% YoY to roughly $0.95 million

    The sharp decline in G&A expenses is attributed to cost-saving measures and reductions in non-essential administrative spending compared to the previous period.

    Total Other Income (Expense)

    Deteriorated dramatically from a loss of $37,830 to about -$8.91 million

    A significant swing in non-operating results, primarily due to a substantial increase in losses related to the fair value adjustment of warrant liabilities (including impacts from Series D warrant exercises) compared to nearly neutral figures in Q1 2024.

    Cash at Period End

    Increased by approximately 135% (from $4.91 million to $11.57 million)

    Strong cash inflows, primarily driven by robust financing activities and effective operational cash management, resulted in a substantial surge in liquidity compared to Q1 2024.

    Total Assets

    Increased by 81% (from $7.29 million to $13.19 million)

    The rise in total assets is largely due to the improved cash position, which significantly bolstered the asset base relative to the previous period.

    Stockholders’ Equity

    Increased by 124% (from $4.58 million to $10.29 million)

    Enhanced by proceeds from common stock issuances, warrant exercises, and share-based compensation despite the net loss, stockholders’ equity more than doubled compared to Q1 2024.

    Weighted-Average Common Shares Outstanding

    Declined by about 6% (from 5.14 million to 4.82 million)

    The decrease in weighted-average shares outstanding is likely due to share consolidations (such as reverse stock splits) or similar restructuring activities that reduced the share count compared to Q1 2024.

    Research analysts covering Transcode Therapeutics.